Patient Experienced Resolution of Ascites, Regression of Esophageal Varices and Remained Clinically

Can Fite Biofarma (AMEX:CANF) reported quarterly losses of $(1.24) per share which beat the analyst

RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.

Gainers bioAffinity Technologies (NASDAQ:BIAF) stock moved upwards by 54.3% to $10.17 during Wednes

Can-Fite BioPharma Ltd. (NYSE:CANF) reported extended survival trends in a key late-stage cancer tri

Can-Fite BioPharma reports longer survival in its Phase 3 liver cancer trial and raises $4 million t

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF) ("Can-Fite" or the "Company"), a cl

RAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF)

Gainers Can Fite Biopharma (AMEX:CANF) shares moved upwards by 20.4% to $3.96 during Wednesday'

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing

Company plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatoc

The New Mechanistic Findings Support Can-Fite’s Ongoing Phase IIb Study Design Following Positive Ph

The New Mechanistic Findings Support Can-Fite's Ongoing Phase IIb Study Design Following Positive Ph

Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Na

Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory intera

Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory intera

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing

Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced d

Ramat Gan, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (

Interim analysis to be conducted under an FDA- and EMA-agreed protocolRamat Gan, Israel, July 06, 20

Interim analysis to be conducted under an FDA- and EMA-agreed protocol Ramat Gan, Israel, July 06, 2

Gainers Chemomab Therapeutics (NASDAQ:CMMB) stock increased by 33.8% to $2.27 during Thursday's

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Can Fite Biopharma (AMEX:CANF)

Gainers Can Fite Biopharma (AMEX:CANF) shares rose 43.8% to $4.27 during Wednesday's regular se

Can-Fite BioPharma Ltd. (NYSE:CANF) on Wednesday said its Phase 2a study of Namodenoson in advanced

Can-Fite's Phase 2a Namodenoson study met its safety endpoint and showed durable survival, suppo

Three emerging biotechnology companies, Can-Fite (NYSE: CANF), NeOnc (NASDAQ: NTHI), and PMGC (NASDA

Gainers Can Fite Biopharma (AMEX:CANF) stock moved upwards by 52.0% to $4.52 during Wednesday's

NKE: -9% | Nike shares are trading lower. The company reported Q4 financial results. BE: 12% | Bloom

Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced d

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock moved upwards by 168.2% to $7.94 during Friday&

Can-Fite stock rises after Japan patent allowance strengthens Namodenoson’s obesity and metabolic di

Gainers Quantum Cyber (NASDAQ:QUCY) stock moved upwards by 63.4% to $2.37 during Friday's pre-m

ON: -14% | ON stock has given up its prior gain. ON Semiconductor shares were trading higher after t

The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets a

The allowed Patent strengthens protection in one of the world's largest pharmaceutical markets and f

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of pr

Ramat-Gan, Israel, June 22, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (

Company to Conduct Partnering Meetings Focused on Oncology, Liver Disease and Inflammatory Disease R

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing

Growing momentum for RAS inhibition at ASCO highlights Namodenoson's RAS pathway inhibition and enco

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of pr

Ramat Gan, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (T

D. Boral Capital analyst Jason Kolbert upgrades Can Fite Biopharma (AMEX:CANF) from Hold to Buy a

Phase 2b study design to be discussed at BIO International Convention in San Diego as Can-Fite advan

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Can Fite Biopharma (AMEX:CANF) w

Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a clinical-stage biotechnology company developing

Vetbiolix, Can-Fite's veterinary commercialization partner, is funding all development costs ass

Strengthens global IP and supports strategic positioning in the rapidly growing metabolic therapeuti